Single-arm Phase 2 study | Neoadjuvant chemotherapy, excision, and observation for early rectal cancer.
23 Aug, 2022 | 12:53h | UTC
Commentary from the author on Twitter (thread – click for more)
Pleased to share our @CDNCancerTrials NEO Trial results: 79% of patients with cT1-3bN0 #rectalcancer had organ sparing therapy with 3 mo of FOLFOX/CAPOX and transanal surgery. @drcarl_vancouvr @JCO_ASCO @OncoAlert https://t.co/gfcywHk7Y0
— Hagen Kennecke (@HKennecke) August 18, 2022